Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

OBJECTIVES: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor antibody) might interrupt the hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Conde, Matilde, Vizcarra, Pilar, Pérez-García, José Manuel, Gion, María, Martialay, María Pilar, Taboada, Javier, Alonso-Fernández, Alberto, Sampayo-Cordero, Miguel, Malfettone, Andrea, Tena, Isabel, Torre, Sergio De La, Llombart-Cussac, Antonio, Cortés, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384458/
https://www.ncbi.nlm.nih.gov/pubmed/35987472
http://dx.doi.org/10.1016/j.ijid.2022.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384458/
https://www.ncbi.nlm.nih.gov/pubmed/35987472
http://dx.doi.org/10.1016/j.ijid.2022.08.007

Ejemplares similares